Home
/
Benitec Biopharma Inc.
/
Financials
/
Quarterly
Benitec Biopharma Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Benitec Biopharma Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
$0
Feb 12, 2026
Q1
2026
Sep 30, 2025
$0
Nov 14, 2025
Q3
2025
Mar 31, 2025
$0
May 14, 2025
Q2
2026
Dec 31, 2024
$0
Feb 12, 2026
Q1
2026
Sep 30, 2024
$0
Nov 14, 2025
Q3
2025
Mar 31, 2024
$0
May 14, 2025
Q2
2024
Dec 31, 2023
$0
Feb 14, 2025
Q1
2025
Sep 30, 2023
$0
Nov 14, 2024
Q3
2024
Mar 31, 2023
$54.0K
May 13, 2024
Q2
2024
Dec 31, 2022
$14.0K
Feb 13, 2024
Q1
2024
Sep 30, 2022
$0
Nov 13, 2023
Q3
2023
Mar 31, 2022
$48.0K
May 15, 2023
Q2
2023
Dec 31, 2021
$25.0K
Feb 13, 2023
Q1
2023
Sep 30, 2021
$0
Nov 10, 2022
Q3
2022
Mar 31, 2021
$1.0K
May 16, 2022
Q2
2022
Dec 31, 2020
$1.0K
Feb 14, 2022
Q1
2022
Sep 30, 2020
$55.0K
Nov 15, 2021
Q3
2021
Mar 31, 2020
$28.0K
May 12, 2021
Q2
2021
Dec 31, 2019
$77.0K
Feb 9, 2021
Q1
2021
Sep 30, 2019
$33.0K
Nov 13, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
($11.84M)
Feb 12, 2026
Q2
2026
Sep 30, 2025
($8.97M)
Feb 12, 2026
Q1
2026
Sep 30, 2025
($8.97M)
Nov 14, 2025
Q3
2025
Mar 31, 2025
($9.35M)
May 14, 2025
Q2
2026
Dec 31, 2024
($9.55M)
Feb 12, 2026
Q3
2025
Dec 31, 2024
($7.36M)
May 14, 2025
Q1
2026
Sep 30, 2024
($5.06M)
Nov 14, 2025
Q2
2026
Sep 30, 2024
($5.06M)
Feb 12, 2026
Q3
2025
Sep 30, 2024
($5.06M)
May 14, 2025
Q3
2025
Mar 31, 2024
($4.28M)
May 14, 2025
Q3
2025
Dec 31, 2023
($6.80M)
May 14, 2025
Q2
2024
Dec 31, 2023
($6.80M)
Feb 14, 2025
Q2
2024
Sep 30, 2023
($5.95M)
Feb 14, 2025
Q3
2025
Sep 30, 2023
($5.95M)
May 14, 2025
Q1
2025
Sep 30, 2023
($5.95M)
Nov 14, 2024
Q3
2024
Mar 31, 2023
($4.40M)
May 13, 2024
Q3
2024
Dec 31, 2022
($5.41M)
May 13, 2024
Q2
2024
Dec 31, 2022
($5.41M)
Feb 13, 2024
Q2
2024
Sep 30, 2022
($5.09M)
Feb 13, 2024
Q3
2024
Sep 30, 2022
($5.09M)
May 13, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
($13.38M)
Feb 12, 2026
Q1
2026
Sep 30, 2025
($9.80M)
Nov 14, 2025
Q3
2025
Mar 31, 2025
($10.19M)
May 14, 2025
Q2
2026
Dec 31, 2024
($10.81M)
Feb 12, 2026
Q1
2026
Sep 30, 2024
($5.79M)
Nov 14, 2025
Q3
2025
Mar 31, 2024
($4.14M)
May 14, 2025
Q2
2024
Dec 31, 2023
($6.93M)
Feb 14, 2025
Q1
2025
Sep 30, 2023
($5.87M)
Nov 14, 2024
Q3
2024
Mar 31, 2023
($4.34M)
May 13, 2024
Q2
2024
Dec 31, 2022
($5.61M)
Feb 13, 2024
Q1
2024
Sep 30, 2022
($4.58M)
Nov 13, 2023
Q3
2023
Mar 31, 2022
($3.46M)
May 15, 2023
Q2
2023
Dec 31, 2021
($4.84M)
Feb 13, 2023
Q1
2023
Sep 30, 2021
($4.82M)
Nov 10, 2022
Q3
2022
Mar 31, 2021
($3.79M)
May 16, 2022
Q2
2022
Dec 31, 2020
($3.26M)
Feb 14, 2022
Q1
2022
Sep 30, 2020
($2.69M)
Nov 15, 2021
Q3
2021
Mar 31, 2020
($2.11M)
May 12, 2021
Q2
2021
Dec 31, 2019
($2.11M)
Feb 9, 2021
Q1
2021
Sep 30, 2019
($1.17M)
Nov 13, 2020